These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8599984)

  • 1. Nonsecretory multiple myeloma.
    Bourantas K
    Eur J Haematol; 1996; 56(1-2):109-11. PubMed ID: 8599984
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 3. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
    Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
    Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
    Nara M; Suzuki K; Inoue Y; Enomoto H; Saito T; Fujioka S
    Acta Haematol; 1993; 90(2):102-3. PubMed ID: 8285014
    [No Abstract]   [Full Text] [Related]  

  • 5. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy for multiple myeloma: Practice guidelines].
    Kurokawa M
    Nihon Naika Gakkai Zasshi; 2007 Oct; 96(10):2312-8. PubMed ID: 18044173
    [No Abstract]   [Full Text] [Related]  

  • 7. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 8. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies for plasma cell myeloma.
    Smith L; Alexanian R
    CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the treatment of multiple myeloma.
    Lokhorst HM; Dekker AW
    Cancer Treat Rev; 1993 Apr; 19(2):113-28. PubMed ID: 7683253
    [No Abstract]   [Full Text] [Related]  

  • 12. Inside Haematologica: new concepts in the management of multiple myeloma.
    Haematologica; 2002 Aug; 87(8):786-7. PubMed ID: 12161351
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
    Lila AM; Mazurov VI; Novik AA
    Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
    [No Abstract]   [Full Text] [Related]  

  • 14. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
    Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
    Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unusual case of pulmonary hypertension in a young male.
    Rostagno C; Ciolli S; Prisco D
    Intern Emerg Med; 2006; 1(2):127-32. PubMed ID: 17111785
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A; Stamatellou M; Papanastasiou K
    Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract]   [Full Text] [Related]  

  • 18. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
    Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long unmaintained remission in multiple myeloma.
    Alexanian R
    Am J Clin Oncol; 1986 Oct; 9(5):458-60. PubMed ID: 3776910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.